Elacestrant

About

Therapy type: Hormone therapy

Therapy strategy: ER signaling inhibition

Mappings

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (1) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant
EMA (1) FGFR2::v Intrahepatic Cholangiocarcinoma Elacestrant
EMA (1) FGFR2 rearrangements Intrahepatic Cholangiocarcinoma Elacestrant